Patents Assigned to Fuso Pharmaceutical Industries, Ltd.
  • Patent number: 9096878
    Abstract: The present inventors conducted dedicated studies and successfully constructed expression vectors that enable high-level production of foreign gene-derived proteins in mammalian host cells, which comprise a translation-impaired dihydrofolate reductase gene cistron whose expression has been attenuated by altering the codons to the least frequently used codons in mammals; and a gene cassette which has a cloning site for incorporation of a foreign gene between a highly transcriptionally active promoter and a highly stable polyadenylation signal.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: August 4, 2015
    Assignees: National University Corporation Hokkaido University, Fuso Pharmaceutical Industries, Ltd.
    Inventors: Hiroshi Tahara, Yusuke Suzuki, Keiichi Yamamoto, Yuzuru Kitahara, Yasuhiko Suzuki
  • Publication number: 20150184230
    Abstract: An objective of the present invention is to provide the cytolethal distending toxin (CDT) of C. hyointestinalis and polynucleotides encoding it, and novel methods for detection of C. hyointestinalis using the cdt genes. The present inventors focused on the cytolethal distending toxin (CDT) of Campylobacter bacteria, and detected the cdt genes of a Campylobacter-like bacterium isolated from an enteritis patient in Thailand. The present inventors discovered a bacterial strain whose cdtB gene was amplified by common primers in C. jejuni, C. coli, and C. fetus, but not by multiplex PCR that can specifically detect the cdtA, cdtB, and cdtC genes of the three bacterial species. The bacterial strain was identified as C. hyointestinalis by 16S rRNA gene analysis. Furthermore, the entire nucleotide sequence of the cdt genes was determined by genome walking upstream and downstream of the cdtB gene.
    Type: Application
    Filed: October 11, 2013
    Publication date: July 2, 2015
    Applicants: FUSO PHARMACEUTICAL INDUSTRIES, LTD., Osaka Prefecture University Public Corporation
    Inventors: Shinji YAMASAKI, Worada SAMOSORUNSUK, Masahiro ASAKURA
  • Publication number: 20150147447
    Abstract: The present invention has demonstrated that microorganisms present in a liver can be killed by washing the bile duct and the portal vein with hot water, and then disinfecting the liver using a chlorine-based disinfectant. It has also been demonstrated that sterilizing effects can be enhanced by freezing the liver after disinfection with a chlorine-based disinfectant.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 28, 2015
    Applicant: Fuso Pharmaceutical Industries, Ltd.
    Inventors: Shinji Yamasaki, Atsushi Hinenoya, Iwao Morikochi, Mamoru Yamaguchi, Yukitoshi Sakuramoto, Kazumasa Nishida, Masahiro Asakura
  • Patent number: 9029627
    Abstract: A lentiviral vector was used to produce non-human animals that express human sFLT1 specifically in the murine placenta, to provide model animals of diseases such as pregnancy-induced hypertension syndrome that are close to the clinical conditions, methods for producing the model animals, methods of screening for candidate compounds as therapeutic agents for diseases such as pregnancy-induced hypertension syndrome by using the model animals, and therapeutic agents for diseases such as pregnancy-induced hypertension syndrome. As a result, the model animals were found to exhibit symptoms that are very close to the clinical conditions in human, which are presentation of hypertension as well as placental insufficiency, intrauterine growth retardation, glomerulosclerosis, and proteinuria during pregnancy, and improvement of those symptoms postpartum.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: May 12, 2015
    Assignees: Fuso Pharmaceutical Industries, Ltd.
    Inventors: Masaru Okabe, Masahito Ikawa, Tadashi Kimura, Keiichi Kumasawa
  • Patent number: 9018354
    Abstract: An objective of the present invention is to provide methods of producing human collagen molecules that are easy to isolate and purify and that have a structure substantially equivalent to that of a natural collagen molecule, wherein host cells that are transduced with a collagen gene synthesize large amounts of human collagen protein derived from a gene introduced into a high exogenous gene expression vector. Another objective of the present invention is to provide collagen molecules produced by the production methods. The present inventors discovered that a large amount of human collagen hardly contaminated with host cell-derived collagen could be produced, by selecting from various mammalian cells a host cell that has low collagen expression and introducing a collagen gene construct into a vector capable of high exogenous gene expression.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: April 28, 2015
    Assignees: Fuso Pharmaceutical Industries, Ltd., Osaka Prefectural Government
    Inventors: Tetsuo Kase, Akio Kimura, Hiroshi Ueyama, Mizuki Nishihara, Yoko Kisaki, Aya Keshi
  • Patent number: 8950027
    Abstract: A respiratory tract widening tool capable of reliably managing a respiratory tract in a supine posture and freely changing the posture, and a respiratory tract widening unit provided therewith are provided.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: February 10, 2015
    Assignees: Fuso Pharmaceutical Industries, Ltd., Nextier
    Inventors: Keiichi Yamamoto, Yuzuru Kitahara, Yasuyo Maruyama, Toru Shinzato
  • Patent number: 8932867
    Abstract: The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: January 13, 2015
    Assignees: University of Miyazaki, Fuso Pharmaceutical Industries Ltd.
    Inventors: Michio Muguruma, Hiroshi Murata
  • Publication number: 20140370602
    Abstract: The present inventors discovered that genes could be introduced specifically into trophectodermal cells with high efficiency, by infecting blastocysts with viral vectors carrying an arbitrary polynucleotide, or by using a nucleic acid transfection reagent in blastocysts, from which zona pellucida (extracellular matrix covering preimplantation early embryos to protect them from infection of viruses and the like) is removed. This method has no risk of infecting cells of the inner cell mass, which develops into a fetus in the future, with the introduced polynucleotide because the trophectoderm serves as a barrier. The present invention provides methods for introducing foreign genes into only placenta but not fetus, which enables rescue of genetically mutant animals from embryonic lethality due to placental abnormality and allows their birth. Furthermore, it is possible to analyze expression and effect of genes that regulate placental formation or placental function by using these methods.
    Type: Application
    Filed: July 16, 2014
    Publication date: December 18, 2014
    Applicants: FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Masaru OKABE, Masahito IKAWA
  • Publication number: 20140335198
    Abstract: The invention relates to a stable bicarbonate ion-containing drug solution, particularly a bicarbonate-containing drug solution for dialysis in which the stability has been improved by the presence of a phosphate ion. Further, the invention relates to a drug solution for acute blood purification, particularly a dialysate and a substitution liquid for acute blood purification to be mixed before use containing the drug solution. Still further, the invention relates to a dialysate and a substitution liquid for acute blood purification to be mixed before use in which the formation of insoluble fine particles or precipitates is prevented for a long time after mixing and with which hypokalemeia and hypophosphatemia are not caused.
    Type: Application
    Filed: May 7, 2014
    Publication date: November 13, 2014
    Applicants: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Shigeto ODA, Tomohito SADAHIRO, Masataka NAKAMURA, Syuichi TANAKA, Shogo TOKUOKA, Hiroya OTANI
  • Publication number: 20140315322
    Abstract: The present invention relates to providing a simple and highly reproducible method for measuring the concentration of acetic acid in blood plasma by using a gas chromatography/mass spectrometry (GC/MS), and more specifically relates to a method for measuring the concentration of acetic acid in blood plasma by using a gas chromatography/mass spectrometry (GC/MS), which comprises extracting acetic acid in blood plasma with methyl-tert-butyl ether (MTBE).
    Type: Application
    Filed: December 26, 2012
    Publication date: October 23, 2014
    Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Shigeaki Yagi, Manabu Nishizawa, Hidetoshi Matsuzawa, Hideo Nagase
  • Patent number: 8815598
    Abstract: The present inventors discovered that genes could be introduced specifically into trophectodermal cells with high efficiency, by infecting blastocysts with viral vectors carrying an arbitrary polynucleotide, or by using a nucleic acid transfection reagent in blastocysts, from which zona pellucida (extracellular matrix covering preimplantation early embryos to protect them from infection of viruses and the like) is removed. This method has no risk of infecting cells of the inner cell mass, which develops into a fetus in the future, with the introduced polynucleotide because the trophectoderm serves as a barrier. The present invention provides methods for introducing foreign genes into only placenta but not fetus, which enables rescue of genetically mutant animals from embryonic lethality due to placental abnormality and allows their birth. Furthermore, it is possible to analyze expression and effect of genes that regulate placental formation or placental function by using these methods.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: August 26, 2014
    Assignees: Fuso Pharmaceutical Industries, Ltd.
    Inventors: Masaru Okabe, Masahito Ikawa
  • Patent number: 8771749
    Abstract: The invention relates to a stable bicarbonate ion-containing drug solution, particularly a bicarbonate-containing drug solution for dialysis in which the stability has been improved by the presence of a phosphate ion. Further, the invention relates to a drug solution for acute blood purification, particularly a dialysate and a substitution liquid for acute blood purification to be mixed before use containing the drug solution. Still further, the invention relates to a dialysate and a substitution liquid for acute blood purification to be mixed before use in which the formation of insoluble fine particles or precipitates is prevented for a long time after mixing and with which hypokalemeia and hypophosphatemia are not caused.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: July 8, 2014
    Assignees: National University Corporation Chiba University, Fuso Pharmaceutical Industries, Ltd.
    Inventors: Shigeto Oda, Tomohito Sadahiro, Masataka Nakamura, Syuichi Tanaka, Shogo Tokuoka, Hiroya Otani
  • Patent number: 8653249
    Abstract: The present inventors successfully constructed expression vectors that enable high-level production of foreign gene-derived proteins in mammalian host cells, which comprise a translation-impaired drug resistance gene cistron whose expression has been attenuated by altering the codons to the least frequently used codons in mammals; and a gene cassette which has a cloning site for incorporation of a foreign gene between a highly transcriptionally active promoter and a highly stable polyadenylation signal.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: February 18, 2014
    Assignees: Fuso Pharmaceutical Industries, Ltd., National University Corporation Hokkaido University
    Inventors: Yasuhiko Suzuki, Keiichi Yamamoto, Hiroshi Tahara, Yusuke Suzuki
  • Patent number: 8609606
    Abstract: Disclosed is a polypeptide of use in the development of reagents or medicines favourable to application for prevention or treatment of ischemic disorders such as conditions caused by ateriosclerosis. The polypeptide has at least one part containing an amino acid of sequence ID 1, and also enhances expression levels of the amino acid in mammalian blood vessels removed from ischemic conditions by means of blood reperfusion.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: December 17, 2013
    Assignee: Fuso Pharmaceutical Industries, Ltd.
    Inventors: Nobutaka Wakamiya, Katsuki Otani
  • Patent number: 8604162
    Abstract: Provided are isolated collectin (CL-L2s) genes including a base sequence set out in SEQ ID NO: 1, 3, 5, 7, 9, 12, 36, 38 or 40 relating to a novel collectin which are expected to exhibit an antibacterial activity, an antiviral activity and the like particularly in a human body; and isolated collectin proteins including an amino acid sequence set out in SEQ ID NO: 2, 4, 6, 8, 10, 13, 37, 39 or 41 and derivatives and fragments thereof.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: December 10, 2013
    Assignee: Fuso Pharmaceutical Industries, Ltd.
    Inventors: Nobutaka Wakamiya, Katsuki Ohtani, Takashi Sakamoto, Yuichiro Kishi
  • Patent number: 8586327
    Abstract: An objective of the present invention is to provide the cytolethal distending toxin (CDT) of C. hyointestinalis and polynucleotides encoding it, and novel methods for detection of C. hyointestinalis using the cdt genes. The present inventors focused on the cytolethal distending toxin (CDT) of Campylobacter bacteria, and detected the cdt genes of a Campylobacter-like bacterium isolated from an enteritis patient in Thailand. The present inventors discovered a bacterial strain whose cdtB gene was amplified by common primers in C. jejuni, C. coli, and C. fetus, but not by multiplex PCR that can specifically detect the cdtA, cdtB, and cdtC genes of the three bacterial species. The bacterial strain was identified as C. hyointestinalis by 16S rRNA gene analysis. Furthermore, the entire nucleotide sequence of the cdt genes was determined by genome walking upstream and downstream of the cdtB gene.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: November 19, 2013
    Assignees: Osaka Prefecture University, Fuso Pharmaceutical Industries, Ltd.
    Inventors: Shinji Yamasaki, Worada Samosorunsuk, Masahiro Asakura
  • Patent number: 8563743
    Abstract: Provided is a novel compound having an effective anti-cancer activity. The novel compound according to the present invention includes a compound represented by formula (I): [wherein R1 represents an alkoxyalkyl group having 2 to 6 carbon atoms] or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: October 22, 2013
    Assignee: Fuso Pharmaceutical Industries, Ltd.
    Inventors: Yoshitaka Ohishi, Takao Toda, Seiichi Takeda
  • Publication number: 20130230918
    Abstract: Novel collectin related molecules i.e., a novel collectin gene comprising a nucleotide sequence set out in SEQ ID NO: 1, and a novel collectin comprising an amino acid sequence set out in SEQ ID NO: 2, which are expected to exhibit anti-bacterial, anti-viral activity or the like especially in human body, and methods in which these molecules are used are provided.
    Type: Application
    Filed: February 10, 2012
    Publication date: September 5, 2013
    Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventor: Nobutaka Wakamiya
  • Publication number: 20130183764
    Abstract: The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin.
    Type: Application
    Filed: September 13, 2011
    Publication date: July 18, 2013
    Applicants: FUSO PHARMACEUTICAL INDUSTRIES, LTD., UNIVERSITY OF MIYAZAKI
    Inventors: Michio Muguruma, Hiroshi Murata
  • Patent number: D731647
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: June 9, 2015
    Assignees: FUSO PHARMACEUTICAL INDUSTRIES, LTD., 3-D MATRIX, LTD.
    Inventors: Fukumitsu Nishioka, Shoujirou Tanioka, Masahiro Nohara, Kiyoshi Takano